

March 28, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated March 28, 2018 titled "Cadila Healthcare's Topical facility successfully completes USFDA inspection".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Cadila Healthcare's Topical facility successfully completes USFDA inspection

Ahmedabad, March 28, 2018

Cadila Healthcare Limited announced today that the USFDA inspected its Topical manufacturing facility located at Changodar, Ahmedabad from 22nd March to 28th March, 2018. At the end of the inspection, no observation (483) is issued.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.